These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8689662)

  • 1. Intensification of the conditioning regimen by the addition of anthracyclines results in a higher incidence of sustained molecular remissions after allogeneic bone marrow transplantation for chronic myeloid leukaemia with marrow depleted of lymphocytes by counterflow centrifugation.
    Schattenberg A; Mensink E; de Witte T
    Cas Lek Cesk; 1996 Apr; 135(8):239-43. PubMed ID: 8689662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of T cell-depleted transplantation after conditioning with an intensified regimen in patients aged 50 years or more is comparable with that in younger patients.
    Schattenberg A; Schaap N; Preijers F; van der Maazen R; de Witte T
    Bone Marrow Transplant; 2000 Jul; 26(1):17-22. PubMed ID: 10918401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of leukemic relapse after transplantation with lymphocyte depleted marrow by intensification of the conditioning regimen with a 6-day continuous infusion of anthracyclines.
    Raemaekers J; De Witte T; Schattenberg A; Van der Lely N
    Bone Marrow Transplant; 1989 Mar; 4(2):167-71. PubMed ID: 2650787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
    Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
    Martinelli G; Montefusco V; Testoni N; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazi F; Rosti G; Bandini G; Tura S
    Haematologica; 2000 Jun; 85(6):653-8. PubMed ID: 10870124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase].
    Liubimova LS; Savchenko VG; Mendeleeva LP; Kliasova GA; Gribanova EO; Demidova IA; Gal'tseva IV; Kuz'mina LA; Momotiuk KS; Kuliev RG
    Ter Arkh; 1999; 71(7):27-32. PubMed ID: 10481864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery.
    Van der Lely N; De Witte T; Raemaekers J; Schattenberg A; Haanen C
    Bone Marrow Transplant; 1989 Mar; 4(2):163-6. PubMed ID: 2650786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
    Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of chromosome studies on PHA-stimulated blood and unstimulated bone marrow cells in recipients of lymphocyte depleted grafts using counterflow centrifugation.
    Schattenberg A; Bär B; Smeets D; Geurts van Kessel A; De Witte T
    Bone Marrow Transplant; 1993 Feb; 11(2):95-101. PubMed ID: 8435669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia].
    Román J; García MJ; Martín C; Sánchez J; Serrano J; Falcón M; Castillejo JA; Navarro JA; Flores R; Torres A
    Med Clin (Barc); 1998 Oct; 111(11):405-9. PubMed ID: 9834912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.